Three major hospital systems on Monday filed separate federal lawsuits accusing CVS Health and its affiliates of secretly conspiring to [...] …
Blog Posts
California-based Amgen recently became the eighth pharmaceutical manufacturer to expand its 340B claims data requirements to in-house pharmacy use—and the [...] …
Please Login or Become a Paid Subscriber to View this Content
SPONSORED CONTENT
For health systems and pharmacies participating in 340B, compliance is not optional. It is a core operational responsibility that affects audit readiness, pharmacy performance, and patient access. In a highly specialized environment shaped by regulatory scrutiny, operational complexity,
…
A Georgia congressman, who has been a longtime 340B program critic, will face off today against four other GOP contenders [...] …
Please Login or Become a Paid Subscriber to View this Content
One of the 340B program’s biggest critics and advocates for change will not return to Congress in 2027 after placing [...] …
Please Login or Become a Paid Subscriber to View this Content
340B drug pricing program stakeholders—from both sides of the debate over its future—cheered on the May 14 addition of an [...] …
Please Login or Become a Paid Subscriber to View this Content
Two major pharmaceutical companies exempted certain states and reversed exemptions in others, following court rulings, threats of enforcement actions and [...] …
Please Login or Become a Paid Subscriber to View this Content
Minnesota state lawmakers failed to pass a bill that would have strengthened the state’s existing 340B contract pharmacy access law [...] …
Please Login or Become a Paid Subscriber to View this Content
An Arkansas Republican, who has historically supported 340B providers, announced Friday that he has joined the bipartisan U.S. Senate working [...] …
Please Login or Become a Paid Subscriber to View this Content
A high-ranking U.S. senator, who’s been a chief critic of the 340B program, will square off Saturday against two GOP [...] …